Hexagon Bio, a California-based biotechnology company turning nature’s DNA into medicines for cancers and infectious diseases with unmet needs, will move into clinical research with $47 million in Series A financing.
GlaxoSmithKline opened a new $13 million research hub in London focused on artificial intelligence.
In this webinar, learn how diverse drug development companies with unique models of discovery, innovative drug modalities and non-traditional/natural product source material use phenotypic screening and profiling to understand their compounds’ disease impact.
Hadean, a UK-based company, has developed a cloud-native supercomputing platform. Their Hadean Platform, a distributed computing platform, streamlines running applications via cloud by removing excessive middleware and helping scale the process – a journey that has taken them from the world of gaming to the modeling a pandemic.
A paper published in the journal Science on August 8 suggests that it may be possible to speed up the drug discovery process.
Boston-based Dewpoint Therapeutics and Merck will collaborate to develop a novel mechanism for the treatment of HIV by harnessing Dewpoint’s proprietary platform for condensate-based drug discovery.
Japanese drug-discovery company PeptiDream Inc. will collaborate with Merck & Co. in developing COVID-19 therapies.
Shares of Denmark-based Genmab climbed after the company announced a broad oncology alliance with AbbVie that is valued at close to $4 billion, one of the largest oncology partnerships in the industry.
This webinar will discuss a set of in vitro assays that tackle the challenges of in vitro hepatotoxicity assessment.
Atomwise, a leader in using artificial intelligence for small-molecule discovery, and Bridge Biotherapeutics, a clinical-stage biotech company, announced a research collaboration to launch up to 13 small-molecule programs across multiple therapeutic areas using structure-based AI technology for drug discovery.